Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Asthma Clinical Research Network (ACRN) Trial - Macrolides in Asthma (MIA)
Brief Summary: Asthma can be caused by a variety of factors, including tobacco smoke, allergens, and respiratory airway infections. Many people use inhaled corticosteroid medications to treat their symptoms. These medications, however, are not effective for everyone. Clarithromycin is an antibiotic that may effectively treat asthma in these individuals. This study will evaluate the effectiveness of clarithromycin at controlling asthma symptoms.


Options:
A: Arm Label: Azithromycin (Zithromax); Type: EXPERIMENTAL; Interventions: Drug: Zithromax | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Zithromax; Assigned to Arm(s): Azithromycin (Zithromax) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Placebo (for Dupilumab 200 mg) q2w; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Inhaled corticosteroid (ICS) therapy, Drug: Albuterol/Salbutamol, Drug: Levalbuterol/Levosalbutamol | Arm Label: Dupilumab 200 mg q2w; Type: EXPERIMENTAL; Interventions: Drug: Dupilumab, Drug: Inhaled corticosteroid (ICS) therapy, Drug: Albuterol/Salbutamol, Drug: Levalbuterol/Levosalbutamol | Arm Label: Placebo (for Dupilumab 300 mg) q2w; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Inhaled corticosteroid (ICS) therapy, Drug: Albuterol/Salbutamol, Drug: Levalbuterol/Levosalbutamol | Arm Label: Dupilumab 300 mg q2w; Type: EXPERIMENTAL; Interventions: Drug: Dupilumab, Drug: Inhaled corticosteroid (ICS) therapy, Drug: Albuterol/Salbutamol, Drug: Levalbuterol/Levosalbutamol | Intervention Type: DRUG; Name: Dupilumab; Assigned to Arm(s): Dupilumab 200 mg q2w, Dupilumab 300 mg q2w | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo (for Dupilumab 200 mg) q2w, Placebo (for Dupilumab 300 mg) q2w | Intervention Type: DRUG; Name: Inhaled corticosteroid (ICS) therapy; Assigned to Arm(s): Dupilumab 200 mg q2w, Dupilumab 300 mg q2w, Placebo (for Dupilumab 200 mg) q2w, Placebo (for Dupilumab 300 mg) q2w | Intervention Type: DRUG; Name: Albuterol/Salbutamol; Assigned to Arm(s): Dupilumab 200 mg q2w, Dupilumab 300 mg q2w, Placebo (for Dupilumab 200 mg) q2w, Placebo (for Dupilumab 300 mg) q2w | Intervention Type: DRUG; Name: Levalbuterol/Levosalbutamol; Assigned to Arm(s): Dupilumab 200 mg q2w, Dupilumab 300 mg q2w, Placebo (for Dupilumab 200 mg) q2w, Placebo (for Dupilumab 300 mg) q2w
C: Intervention Type: DRUG; Name: Macrolides (azithromycin or clarithromycin); Assigned to Arm(s): N/A
D: Arm Label: clarithromycin + fluticasone; Type: EXPERIMENTAL; Interventions: Drug: clarithromycin, Drug: fluticasone propionate | Arm Label: placebo + fluticasone; Type: ACTIVE_COMPARATOR; Interventions: Drug: fluticasone propionate, Drug: placebo clarithromycin | Intervention Type: DRUG; Name: clarithromycin; Assigned to Arm(s): clarithromycin + fluticasone | Intervention Type: DRUG; Name: fluticasone propionate; Assigned to Arm(s): clarithromycin + fluticasone, placebo + fluticasone | Intervention Type: DRUG; Name: placebo clarithromycin; Assigned to Arm(s): placebo + fluticasone

Answer: D